New drugs are continually being researched and developed for Non-Hodgkin’s lymphoma. These must be shown to be safe and effective before doctors can prescribe them to patients. Through clinical trials, researchers test the effects of new drugs on a group of volunteers with non-Hodgkin’s lymphoma. Following a strict protocol and using carefully controlled conditions, researchers evaluate the investigational drugs under development and measure the ability of the new drug to treat non-Hodgkin’s lymphoma,...
Updated statistics with estimated new cases and deaths for 2013 (cited American Cancer Society as reference 2).
Added text to state that follicular lymphoma in situ and primary follicular lymphoma of the duodenum are particularly indolent variants that rarely progress and rarely require therapy (cited Schmatz et al. and Jegalian et al. as references 17 and 18, respectively).
Revised text to state that myeloablative therapy with autologous or allogeneic hematopoietic stem cell support is under clinical evaluation (cited Kyriakou et al. as reference 48).
Added Nakamura et al. as reference 62.
Added Kempf et al. as reference 97.
Added Glantz et al. as reference 18.
Added text to state that similar response rates in relapsing patients were seen for the histone deacetylase inhibitor ramidepsin for 130 evaluable patients in a prospective trial (cited Coiffler et al. as reference 70).
Added Di Sabatino et al. as reference 87.
Added Bazarbachi et al. as reference 125.
Added Griffiths et al. as reference 143.
Added LaCasce et al. as reference 144.
Stage Information for Adult NHL
Revised text to state that interim positive emission tomography (PET) scans after two to four cycles of therapy did not provide reliable prognostic information because of problems of interobserver reproducibility in a large cooperative group trial, ECOG-E3444, and lack of difference in outcome between PET-negative and PET-positive/biopsy-negative patients in two prospective trials (cited Pregno et al. as reference 9).
Added Salles et al. and Advani et al. as references 13 and 14, respectively.
Treatment for Indolent, Stage I and Contiguous Stage II Adult NHL
Added Kelsey et al. and Seymour et al. as references 6 and 7, respectively.
Treatment for Indolent, Noncontiguous Stage II/III/IV Adult NHL
Revised text to state that rituximab may be considered as first-line therapy, either alone or in combination with other agents.